Disc Medicine Inc.
- Address
- 321 Arsenal Street Suite 101
Sponsor Overview
Specializations
Erythropoietic Protoporphyria
Disc Medicine Inc. is focused on clinical research in Erythropoietic Protoporphyria, with interest in the management of photosensitivity, pain-free sunlight exposure, and the biochemical burden associated with protoporphyrin accumulation.
- Photosensitivity and sunlight tolerance
- Protoporphyrin IX reduction
- Safety and tolerability in long-term care
The sponsor’s research in this area centers on the clinical needs of people living with EPP, including both FECH and ALAS2 genotype groups.
X-Linked Protoporphyria
Another key area of interest is X-Linked Protoporphyria, where the sponsor examines treatment effects on light sensitivity, symptom control, and biochemical markers linked to heme biosynthesis disruption.
- Light-induced pain and exposure tolerance
- Whole-blood metal-free protoporphyrin IX
- Clinical safety and tolerability
This disease focus reflects involvement in rare porphyria care, with attention to the burden of cutaneous photosensitivity and related functional limitations.
Rare metabolic disorders
The sponsor’s trial portfolio is concentrated in rare inherited disorders affecting porphyrin metabolism, particularly conditions that present with chronic light-triggered symptoms and impaired daily activity.
- Inherited porphyria syndromes
- Heme pathway dysfunction
- Symptom burden in rare disease
Clinical interest extends to biological markers of disease activity and the impact of treatment on day-to-day exposure to sunlight.
Clinical safety and tolerability
Across its studies, Disc Medicine Inc. places emphasis on long-term safety, tolerability, and sustained clinical management in patients with chronic rare disease.
- Long-term treatment monitoring
- Adverse effect assessment
- Ongoing therapeutic evaluation
This area supports the sponsor’s work in therapies intended for persistent, specialist-managed porphyria care.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Bitopertin in Participants with Erythropoietic Protoporphyria or X-Linked Protoporphyria |  Belgium France Germany Ireland Italy Norway Spain Sweden The Netherlands | Recruiting |
| APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | Belgium France Germany Ireland Italy Norway Spain Sweden The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 12 sites across their trial portfolio.
Therapeutic Focus
- 1.Nutritional and Metabolic Diseases2 trials211 other sponsors
Partnered Research Centres
12 centres- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Cooley Road, Crumlin, D12 PN40 Dublin
- Address
- Dr. Molewaterplein 40, 3015 GD Rotterdam
- Address
- Via Francesco Sforza 28, 20122 Milan
- Address
- Haukelandsveien 22, 5021 Bergen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Disc Medicine Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.